See every side of every news story

Published 3 days ago • loading... • Updated 3 days ago

Gilead Sciences (NASDAQ:GILD) Upgraded to “Buy” at Deutsche Bank Aktiengesellschaft

Summary by defenseworld.net

Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a buy rating in a report released on Tuesday, MarketBeat.com reports. The brokerage currently has $120.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $80.00. GILD has been the topic of a number of other research reports. Bank of America reiterated a “buy” rating and set a $109.00 tar…

1 Articles

1 Articles

All

Left

Center

1

Right

defenseworld.net

Gilead Sciences (NASDAQ:GILD) Upgraded to “Buy” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a buy rating in a report released on Tuesday, MarketBeat.com reports. The brokerage currently has $120.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $80.00. GILD has been the topic of a number of other research reports. Bank of America reiterated a “buy” rating and set a $109.00 tar…

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated3 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

defenseworld.net broke the news in 3 days ago on Wednesday, February 19, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics